Literature DB >> 25568433

Candida fermentati as a cause of persistent fungemia in a preterm neonate successfully treated by combination therapy with amphotericin B and caspofungin.

Noura Al-Sweih1, Suhail Ahmad2, Leena Joseph2, Seema Khan3, Sandhya Vayalil4, Rachel Chandy2, Ziauddin Khan5.   

Abstract

A case of persistent candidemia in a preterm neonate caused by Candida fermentati, identified by sequencing of the internally transcribed spacer region of ribosomal DNA (rDNA), is described. The neonate was treated for 30 days by combination therapy with amphotericin B (AmBisome) and caspofungin with a successful outcome, and no drug-related side effects were observed.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25568433      PMCID： PMC4390630          DOI： 10.1128/JCM.03351-14

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  29 in total

1.  Candida fermentati from HIV patients in Chennai, South India.

Authors:  K Umamaheswari; Thangam Menon
Journal:  Int J Infect Dis       Date:  2008-07-22       Impact factor: 3.623

2.  [Clinical characteristics of Candida septicemia seen in a neonatal intensive care unit: analysis of 9 cases].

Authors:  Xiao-lu Ma; Wei Sun; Tao Liu
Journal:  Zhonghua Er Ke Za Zhi       Date:  2006-09

3.  Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program.

Authors:  M A Pfaller; D J Diekema; M Mendez; C Kibbler; P Erzsebet; S-C Chang; D L Gibbs; V A Newell
Journal:  J Clin Microbiol       Date:  2006-10       Impact factor: 5.948

4.  Species and susceptibility distribution of 1062 clinical yeast isolates to azoles, echinocandins, flucytosine and amphotericin B from a multi-centre study.

Authors:  A F Schmalreck; B Willinger; G Haase; G Blum; C Lass-Flörl; W Fegeler; K Becker
Journal:  Mycoses       Date:  2012-01-11       Impact factor: 4.377

5.  Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age.

Authors:  Xavier Sáez-Llorens; Mercedes Macias; Padmanabha Maiya; Juan Pineros; Hasan S Jafri; Archana Chatterjee; Gloria Ruiz; Janaki Raghavan; Susan K Bradshaw; Nicholas A Kartsonis; Peng Sun; Kim M Strohmaier; Marissa Fallon; Sheng Bi; Julie A Stone; Joseph W Chow
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

6.  Debaryomyces hansenii (Candida famata), a rare human fungal pathogen often misidentified as Pichia guilliermondii (Candida guilliermondii).

Authors:  Marie Desnos-Ollivier; Marie Ragon; Vincent Robert; Dorothée Raoux; Jean-Charles Gantier; Françoise Dromer
Journal:  J Clin Microbiol       Date:  2008-08-13       Impact factor: 5.948

7.  Fungemia due to Candida guilliermondii in a pediatric and adult population during a 12-year period.

Authors:  Javier Pemán; María Bosch; Emilia Cantón; Angel Viudes; Isidro Jarque; Micaela Gómez-García; José María García-Martínez; Miguel Gobernado
Journal:  Diagn Microbiol Infect Dis       Date:  2007-09-21       Impact factor: 2.803

8.  Candida guilliermondii and other species of candida misidentified as Candida famata: assessment by vitek 2, DNA sequencing analysis, and matrix-assisted laser desorption ionization-time of flight mass spectrometry in two global antifungal surveillance programs.

Authors:  Mariana Castanheira; Leah N Woosley; Daniel J Diekema; Ronald N Jones; Michael A Pfaller
Journal:  J Clin Microbiol       Date:  2012-10-24       Impact factor: 5.948

9.  Identification and Susceptibility Profile of Candida fermentati from a worldwide collection of Candida guilliermondii clinical isolates.

Authors:  Shawn R Lockhart; Shawn A Messer; Michael A Pfaller; Daniel J Diekema
Journal:  J Clin Microbiol       Date:  2008-11-26       Impact factor: 5.948

10.  ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp.

Authors:  W W Hope; E Castagnola; A H Groll; E Roilides; M Akova; M C Arendrup; S Arikan-Akdagli; M Bassetti; J Bille; O A Cornely; M Cuenca-Estrella; J P Donnelly; J Garbino; R Herbrecht; H E Jensen; B J Kullberg; C Lass-Flörl; O Lortholary; W Meersseman; G Petrikkos; M D Richardson; P E Verweij; C Viscoli; A J Ullmann
Journal:  Clin Microbiol Infect       Date:  2012-12       Impact factor: 8.067
View more
  5 in total

1.  Successful therapy of Candida pulcherrima fungemia in a premature newborn with liposomal amphotericin B and micafungin.

Authors:  Alexandra Mpakosi; Maria Siopi; Vasiliki Falaina; Nikolaos Siafakas; Emmanuel Roilides; Maria Kimouli; Martha Theodoraki; Paraskevi Karle; Joseph Meletiadis
Journal:  Med Mycol Case Rep       Date:  2016-08-03

2.  Changing trends in epidemiology and antifungal susceptibility patterns of six bloodstream Candida species isolates over a 12-year period in Kuwait.

Authors:  Ziauddin Khan; Suhail Ahmad; Noura Al-Sweih; Eiman Mokaddas; Khalifa Al-Banwan; Wadha Alfouzan; Inaam Al-Obaid; Khaled Al-Obaid; Mohammad Asadzadeh; Ahlam Jeragh; Leena Joseph; Soumya Varghese; Sandhya Vayalil; Omar Al-Musallam
Journal:  PLoS One       Date:  2019-05-01       Impact factor: 3.240

Review 3.  A Pragmatic Approach to Susceptibility Classification of Yeasts without EUCAST Clinical Breakpoints.

Authors:  Karen Marie Thyssen Astvad; Sevtap Arikan-Akdagli; Maiken Cavling Arendrup
Journal:  J Fungi (Basel)       Date:  2022-01-30

4.  Fatal Lodderomyces elongisporus Fungemia in a Premature, Extremely Low-Birth-Weight Neonate.

Authors:  Mohammad Asadzadeh; Noura Al-Sweih; Suhail Ahmad; Seema Khan; Wadha Alfouzan; Leena Joseph
Journal:  J Fungi (Basel)       Date:  2022-08-26

5.  Increasing prevalence, molecular characterization and antifungal drug susceptibility of serial Candida auris isolates in Kuwait.

Authors:  Ziauddin Khan; Suhail Ahmad; Noura Al-Sweih; Leena Joseph; Wadha Alfouzan; Mohammad Asadzadeh
Journal:  PLoS One       Date:  2018-04-09       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.